跳至主要内容
临床试验/CTRI/2025/08/092186
CTRI/2025/08/092186尚未招募不适用

Comparing Letrozole and Mifepristone pretreatment for medical management of first trimester miscarriages.

INHS ASVINI1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2025年8月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
150
试验地点
1
主要终点
The primary outcome is achievement of complete abortion

研究概览

简要总结

This will be a randomized control interventional trial. The investigators hypothesise that letrozole is equivalent to mifepristone for the pre-treatment of mTOP and propose to conduct a randomised, non-inferiority trial for mTOP up to 10 weeks gestation with two arms as detailed below:

(i)    Oral letrozole 10mg daily for 3 days, followed by vaginal misoprostol on Day 3 (Intervention group)

(ii)  Oral mifepristone 200mg once on Day 1, followed by vaginal misoprostol 800mcg on Day 3. (current practise)

The investigators aim to include 150 patients with 75 in each arm, to detect a non inferiority margin of 15% with a power of 80% with 5% significance.

The primary outcome is complete abortion rates(by day 7-10). Secondary outcomes include time-to-abortion interval, the number of misoprostol doses required, healthcare resource utilisation and side effects.

Letrozole priming before mTOP has been proposed as an alternative to the use of mifepristone. The proposed mechanism is a reduction in serum estrogen levels, leading to a concomitant reduction in progesterone receptor concentration necessary for the maintenance of pregnancy. Several randomised controlled trials (RCTs) have been performed by comparing the effectiveness of using letrozole for mTOP priming before misoprostol versus misoprostol alone. The combination of letrozole with misoprostol has shown to be effective in improving the success rates of complete abortion up to 10 weeks gestation, compared with misoprostol alone. Given its low price, ready availability worldwide and common usage in the fields of ovulation induction and breast cancer, letrozole may be a potential alternative to mifepristone in mTOP priming. While medication costs vary from country to country, the cost of a course of letrozole is largely cheaper than mifepristone. To address the aforementioned knowledge gaps, this study aims to conduct a non-inferior RCT to investigate whether pre-treatment with letrozole before misoprostol is comparable to mifepristone pre-treatment before misoprostol mTOP in patients up to 10 weeks gestation.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
21.00 Year(s) 至 45.00 Year(s)(—)
性别
Female

入选标准

  • Women more than 21 years of age with
  • Unwanted singleton pregnancies of upto 10 wks.

排除标准

  • The exclusion criteria includes history or evidence of adrenal pathology, steroid-dependent cancer, porphyria, poorly controlled hypertension, bronchial asthma, thromboembolism and severe cardiac/renal/liver disease, Haemoglobin level less than 9.5 g/L, presence of an intrauterine contraceptive device, breastfeeding and reported allergic reaction to mifepristone, misoprostol or letrozole.

结局指标

主要结局

The primary outcome is achievement of complete abortion

时间窗: Time taken to achieve complete abortion 1week or 2 week

次要结局

  • Secondary outcomes include time-to-abortion interval, the number of misoprostol doses required, healthcare resource utilisation and side effects.(2 yrs)

研究者

发起方
INHS ASVINI
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

DR SHAZIA KHAN

INSTITUTE OF NAVAL MEDICINE

研究点 (1)

Loading locations...

相似试验